Beesy, founded in 2018 and headquartered in Summit, New Jersey, works with biopharmaceutical commercial teams with a focus on identifying non-conscious drivers behind customer decision-making.

The company conducts qualitative and quantitative research, behavioural audits and activation plans to support existing brands and new commercial launches.

The partnership will support Beesy’s investment in developing AI-based products, internal efficiencies and expanding its market offer across more therapeutic areas and geographies.

The terms of the investment have not been disclosed.

Elys Roberts, founder and chief executive, Beesy (pictured), said: “From our earliest conversations, it was clear DGP shares our ambition to scale a platform that turns our insights into action.

“With DGP’s experience across life sciences and healthcare IT, we’re well positioned to accelerate product and service development and deepen the impact we deliver to our partners.”

Jesse Lane, managing partner at DGP, said: “Beesy is building a distinct position at the intersection of behavioral science, AI-enabled insights, and practical commercial execution.”